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ABSTRACT
Objectives The present study analysed 4 years of a 
hospital register (2015–2018) to determine the risk of 
30- day hospital readmission associated with the medical 
conditions and drug regimens of polymedicated, older 
inpatients discharged home.
Design Registry- based cohort study.
Setting Valais Hospital—a public general hospital centre 
in the French- speaking part of Switzerland.
Participants We explored the electronic records of 20 422 
inpatient stays by polymedicated, home- dwelling older 
adults held in the hospital’s patient register. We identified 
13 802 hospital readmissions involving 8878 separate 
patients over 64 years old.
Outcome measures Sociodemographic characteristics, 
medical conditions and drug regimen data associated with 
risk of readmission within 30 days of discharge.
Results The overall 30- day hospital readmission rate 
was 7.8%. Adjusted multivariate analyses revealed 
increased risk of hospital readmission for patients with 
longer hospital length of stay (OR=1.014 per additional 
day; 95% CI 1.006 to 1.021), impaired mobility (OR=1.218; 
95% CI 1.039 to 1.427), multimorbidity (OR=1.419 per 
additional International Classification of Diseases, 10th 
Revision condition; 95% CI 1.282 to 1.572), tumorous 
disease (OR=2.538; 95% CI 2.089 to 3.082), polypharmacy 
(OR=1.043 per additional drug prescribed; 95% CI 1.028 to 
1.058), and certain specific drugs, including antiemetics and 
antinauseants (OR=3.216 per additional drug unit taken; 
95% CI 1.842 to 5.617), antihypertensives (OR=1.771; 
95% CI 1.287 to 2.438), drugs for functional gastrointestinal 
disorders (OR=1.424; 95% CI 1.166 to 1.739), systemic 
hormonal preparations (OR=1.207; 95% CI 1.052 to 1.385) 
and vitamins (OR=1.201; 95% CI 1.049 to 1.374), as well as 
concurrent use of beta- blocking agents and drugs for acid- 
related disorders (OR=1.367; 95% CI 1.046 to 1.788).
Conclusions Thirty- day hospital readmission risk was 
associated with longer hospital length of stay, health 
disorders, polypharmacy and drug regimens. The 
drug regimen patterns increasing the risk of hospital 
readmission were very heterogeneous. Further research is 
needed to explore hospital readmissions caused solely by 
specific drugs and drug–drug interactions.
INTRODUCTION
Longitudinal studies have demonstrated that 
approximately 20% of home- dwelling older 
adults supported by home healthcare services 
experienced hospital readmission within 30 
days of their discharge.1–3 For many older 
adults, readmission to an acute hospital is 
associated with a functional decline that has 
not always recovered by the time they are 
discharged.4 However, the systematic review 
by Hansen et al5 revealed wide- ranging esti-
mates (5%–79%) of how many hospital 
readmissions were preventable. The period 
between hospital discharge and readmis-
sion has not always been clearly stated in the 
literature, ranging from 30 days to 3 years. 
However, 30 days is the most frequently used 
in public health policy when measuring 
healthcare system performance.6–8
Strengths and limitations of this study
 ► The records of 20 422 hospitalisations involving 
8878 different polymedicated, home- dwelling, older 
patients readmitted to hospital at least once were 
studied to determine the risk of 30- day hospital 
readmission.
 ► The study included 4- year data from a comprehen-
sive hospital register (2015–2018).
 ► A whole series of sociodemographic and clinical pa-
rameters, medical conditions, and prescribed drugs 
were used to predict the probability of hospital 
readmission.
 ► Analyses were correlational and causality was not 
explored.
 ► Although the study considered statistical associ-
ations between drugs and hospital readmissions, 
it did not consider clinically diagnosed drug–drug 
interactions.
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Numerous determinants have been identified and 
associated with hospital readmissions, for example, socio-
demographic and individual characteristics, multimor-
bidity, and medical events.9 10 A substantial risk of 30- day 
hospital readmission has been associated with older inpa-
tients treated for different diseases and surgical inter-
ventions involving hip fracture, cancer, bypass, acute 
cardiovascular events or complex surgery.11 The reasons 
for hospital readmission after a surgical intervention are 
often not directly related to the surgery itself but rather 
to underlying chronic health conditions.12 Thus, chronic 
diseases may play an important role in readmission risk, 
independent of the reason for the initial hospitalisa-
tion.13 14 Older adults’ chronic diseases are not isolated 
health conditions; they can influence each other, and 
treatment for one disease may adversely affect another.15 
For all these reasons, patterns of 30- day hospital readmis-
sions may be very complex.16
Multimorbidity, in the case of two or more diseases,17 18 
may require taking multiple medicines,19 known as poly-
pharmacy (PP) when daily intake involves five or more 
drugs.20 Increasing incidences of multimorbidity with 
age, and consequently PP, add to the complexity of 
managing older inpatients’ drug prescriptions, particu-
larly at hospital discharge.21 22 PP and inadequate drug 
management are significant risk factors for adverse 
drug events (ADEs)—the most common postdischarge 
complications—alongside hospital- acquired infections 
and procedural complications.23 24 ADEs resulting from 
inappropriate drug prescribing, discrepancies between 
prescribed and current regimens, poor adherence, and 
the inadequate surveillance of adverse effects frequently 
lead to hospital admissions, readmissions8 and other 
undesirable consequences such as increased morbidity, 
decreased autonomy, institutionalisation and even early 
death.25 26 A systematic review by El Morabet et al27 indi-
cated ADE rates of 18%–38% after hospital discharge and 
4.5%–24% hospital readmission rates due to those ADEs. 
Because older adults use more drugs, they are at a greater 
risk of drug- related readmission. Numerous studies have 
found that nearly 30% of older inpatients experienced 
ADEs within 3 weeks of hospital discharge, almost three- 
quarters of which could have been prevented or less-
ened.10 28 29
Despite the significant overall impact of ADEs on 
hospital readmission rates, little is known about the asso-
ciation of hospital readmission risk with medical condi-
tions and drug regimens.30 31 El Morabet et al revealed 
the high prevalence of antibiotics, diuretics, vitamin K 
antagonists, opioids, antidiabetics, anticancer drugs, 
antihypertensives, digitalis glycosides, corticosteroids 
and psychotropic drugs in drug- related hospital read-
missions.27 Samoy et al32 reported that anticoagulants, 
hypoglycaemics, beta- blocking agents, antidepressants, 
calcium channel blockers and lenograstim were associ-
ated with high risk of hospital readmission. A retrospec-
tive patient record study by Teymoorian et al33 reported 
that anticoagulants and antiplatelet agents, diuretics and 
antihypertensives, and opioids were associated with a 
high risk of persons aged 80 years old or more being read-
mitted to hospital within 30 days. Blanc et al reported the 
readmission scores of different drugs in a large sample 
of 10 374 adult hospital admissions in general medicine. 
Taking beta- blocking agents, calcium channel blockers, 
diuretics, hypoglycaemic drugs or opioids was a signifi-
cant risk for 30- day readmission.9
Besides the higher risk of drug- related hospital readmis-
sion, some studies have also investigated the associations 
between combining drugs—a common practice when 
treating complex diseases or coexisting medical condi-
tions—and drug- related hospital readmissions. Although 
using multiple drugs may be good clinical practice and 
compliant with guidelines for treating certain diseases, 
one significant consequence of combining drugs is that 
patients face much higher risk of ADEs, which can be 
caused by drug–drug interactions.34–36 ADEs can emerge 
because a drug’s pharmacokinetics and pharmacody-
namics change if taken with another drug.36 Moura et al37 
found that participants with potential drug–drug inter-
actions on their prescription list had 2.4 times higher 
adjusted OR of being readmitted.
Even though some studies have reported high numbers 
of readmissions among home- dwelling older patients for a 
variety of drugs,38 this health issue was mostly investigated 
using prospective or cross- sectional studies with small 
samples. More insight is needed into the patterns of drug- 
related hospital readmissions and risk factors in order 
to design better interventions for addressing ADEs.39 40 
As part of a broader project,41 the present study’s goal 
was to use hospital register data to prioritise risk factors 
for hospital readmission. We hypothesised that sociode-
mographic characteristics, medical conditions (defined 
using the WHO’s International Classification of Diseases, 
10th Revision (ICD-10) and the Swiss Classification of 
Surgical Interventions (CHOP)) and drug prescriptions 
(based on the WHO’s Anatomical Therapeutic Chemical 
(ATC) Classification System) were significant risk factors 




This longitudinal study (2015–2018) used data on a popu-
lation cohort taken from a hospital registry composed of 
140 variables. These were used to investigate the associ-
ations between risk of 30- day hospital readmission and 
the medical conditions and drug regimens of polymed-
icated older inpatients discharged home. The study was 
performed with close regard to the RECORD (REporting 
of studies Conducted using Observational Routinely 
collected health Data) statement.42
Population and data collection
Our custom, 4- year, registry- based data set included poly-
medicated inpatients (five or more drugs prescribed at 
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hospital discharge), aged 65 years old or more, living in 
their own homes and hospitalised at least once at the 
Valais Hospital (a public general hospital in the French- 
speaking part of Switzerland). This specific population 
was selected due to its increased risk of hospital read-
mission.10 28 29 Older inpatients hospitalised once only or 
who died during hospitalisation were excluded, as were 
those hospitalised for fewer than 24 hours (the criterion 
to count as ‘hospitalised’ in Switzerland). Valais Hospi-
tal’s register contains a comprehensive electronic health 
record composed of 140 variables routinely collected 
during hospital stays. However, no electronic patient 
records were available for adult psychiatry for 2015–2018. 
The extracted patient data contained sociodemographic 
characteristics, medical and surgical diagnoses, and 
routinely assessed clinical data (such as gait, falls risk 
or hearing) from hospitalised patients with at least five 
prescribed drugs at discharge. Medical and surgical diag-
noses were coded based on the ICD-10 and CHOP.43 Drug 
classification was based on the WHO’s ATC Classification 
System.44
The strategy for transforming and synthesising the data 
extracted from the register’s multiple data set sources 
was based on Olsen’s register- based methodological 
considerations45 and has been documented elsewhere.46 
Our data set was composed of 20 422 hospital admission 
records running from January 2015 to December 2018, 
with similar numbers of annual hospital admissions: 5134, 
5095, 5125 and 5068, respectively.
Data set customisation for predictive analysis
The data set was recoded and customised to identify the 
frequency of older patients’ hospital admissions. Each 
subject’s unique identifier was used to distinguish their 
different hospital stays from 2015 to 2018. The data set 
included 13 802 readmissions involving 8878 different 
older inpatients discharged home, readmitted to hospital 
within 30 days and whose data were complete (no missing 
values).
Sociodemographic and clinical data were considered 
independent variables and used to compute the predic-
tive models. Readmission following discharge home was 
defined as the dependent variable of interest and was 
dichotomised (0=no, 1=yes) based on 30- day readmission 
between 2015 and 2018. Furthermore, the custom data 
set was composed of six clinical clusters based on agglom-
erative hierarchical clustering methods for identifying 
clinically relevant characteristics and representing older 
inpatients’ health status. Medical status and drugs data 
were recoded and copied to an exploitable population 
database.46
Sociodemographic variables and length of stay
The sociodemographic data set—almost exclusively 
composed of ordinal variables—included two categor-
ical variables (sex and place of discharge from hospital) 
and three continuous variables (age and admission 
and discharge dates). Sex and age were included in 
the analysis as sociodemographic control variables. Age 
was considered a continuous variable as its progressive 
impact has been proven in preliminary investigations and 
previous studies.47
Health variables
Numerous variables were used to describe older patients’ 
health status during each hospital stay. The health data 
set was composed of 23 categorical variables: 21 measured 
as ordinal variables (mobility, changing position, falls 
in the last year, etc) and two measured as nominal 
variables (altered gait and chronic pain). A cleaner, 
better- structured data set—composed of hierarchical 
clusters—was obtained in a previous study combining 
empirical and best- practice statistical approaches.46 Three 
of six preliminarily computed hierarchical clusters were 
included in the modelling analysis as confounding vari-
ables: the mobility cluster, the dependency on the activ-
ities of daily living cluster and the mental state cluster.46 
These three clusters were selected because of their signifi-
cant contributions to hospital readmissions.48–50 The data 
set of medical information was composed of patients’ 
principal medical diagnosis and four secondary medical 
diagnoses, based on ICD-10. Finally, the year of hospital-
isation was introduced as a control variable, based on the 
fact that earlier admission to hospital during this period 
led to a higher probability of unplanned readmissions 
during the entire period covered.
Included drugs
The hospital data set showed that discharged patients had 
been prescribed 2370 different drugs. Drug prescriptions 
were considered continuous, classified according to the 
WHO’s ATC Classification System51 and then included in 
the predictive model as independent variables. To ensure 
robust statistical results, the model only included drug 
categories prescribed to at least 30 inpatients who were 
readmitted within 30 days. Online supplemental file 1 
presents the prescribed ATC classified drugs included in 
the predictive model as independent variables.
For statistical purposes, drug–drug interactions 
between different ATC drug classes51 were operation-
alised as dichotomised variables (0=no simultaneous use 
of drugs from both classes, 1=simultaneous use of drugs 
from both classes) and added to the previous model. 
Drug class interactions were selected based on a literature 
review, significant ORs and expert opinions.52
Data analysis strategy
Data were extracted into a Microsoft Excel spreadsheet 
(Microsoft, Redmond, Washington, USA) and then 
imported into SPSS V.26.0 software. We examined statis-
tical associations between hospital readmissions and 
patient age and sex, length of stay (LOS), principal and 
related ICD-10 diagnoses, CHOP interventions, and 
drug prescriptions during hospitalisations. A causality 
analysis between those variables was impossible given 
our retrospective data collection method, our inability 
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to calculate the time between drug intake and readmis-
sion, and the potential drug changes between hospital-
isation sequences. We conducted a bivariate analysis 
relating the independent variables to 30- day readmission 
after discharge home from 2015 to 2018. Next, we calcu-
lated a series of multilevel logistic regression models for 
binary outcomes explaining the readmissions, within 30 
days, of patients discharged home (0=no, 1=yes). These 
hierarchical models included two levels: the first level 
concerned hospital stays themselves, nested in the second 
level, that of individuals. First, we computed a baseline 
multilevel binary logistic regression model to estimate 
how sets of predictors influenced the probability of 30- day 
hospital readmission, which included individuals’ charac-
teristics, health conditions and hospital LOS. Second, we 
completed this baseline model with the drugs prescribed 
to older inpatients on their discharge home. Finally, to 
the baseline model completed with prescribed drugs, 
we added the known drug–drug interactions between 
different ATC drug classes, based on a literature review 
and expert opinions. The model computed each predic-
tor’s impact, other things being equal, by estimating its 
net impact, controlling for other factors (adjusted ORs). 
The model also considered correlations between each 
subject’s different variables, which were generally not 
independent.53 The model’s random intercept design 
allowed each individual’s intercept to vary, assuming that 
some unmeasured traits remained stable over time and 
allowing a better estimation of the model’s parameters. 
The estimated parameters, on the other hand, had the 
same effect on every subject. Since the data were based 
on the whole population—not a sample—of polymedi-
cated older inpatients discharged home from the Valais 
Hospital, the ORs’ CIs and statistical tests were used to 
indicate the robustness of the relationships (they usually 
only make sense for statistical inference).
Patient and public involvement
Patients were not involved in the development of the 
research questions, study design, outcome measures and 
conduct of the study.
RESULTS
Descriptive results
The electronic records of 20 422 inpatient stays by poly-
medicated, home- dwelling older adults included the 
13 802 hospital readmissions of 8878 different older 
inpatients previously discharged home—an average of 
1.55 inpatient hospital readmissions. The total sample’s 
mean age was 77.77 years old (SD=7.48) and 57% were 
men (table 1). The average hospital LOS was 8.44 days 
(SD=7.58). At discharge, 25% of the sample had impaired 
mobility, 4% were impaired in their activities of daily living 
and 4% showed mental impairment. Our sample popula-
tion averaged 4.58 (SD=0.92) ICD-10 diagnoses and 1.83 
(SD=1.76) surgical interventions (CHOP) performed 
during hospitalisation. The selected medical diagnoses 
distinguished patients affected by circulatory (24%), 
infectious (3%) and respiratory (11%) diseases, as well 
as trauma (8%) and tumours (11%). On average, 8.95 
Table 1 Sociodemographic and hospitalisation data for 
inpatient stays by polymedicated, home- dwelling adults 
aged 65 or more (N=13 802)
Variables
Inpatient stays by 
polymedicated, home- 
dwelling adults aged 65 
or more
Sex
  Stays by men (%) 7834 (56.8)
  Stays by women (%) 5968 (43.2)
Age at discharge (years)
  Mean inpatient age at discharge (SD) 77.77 (7.48)
  Minimum–maximum 65–106
  Median (IQR 25–75) 77.00 (68.00–80.00)
  65–69 (%) 2226 (16.1)
  70–79 (%) 5811 (42.1)
  80–89 (%) 4845 (35.1)
  90 and more (%) 920 (6.7)
Year of discharge
  2015 (%) 3501 (25.4)
  2016 (%) 3318 (24.0)
  2017 (%) 3530 (25.6)
  2018 (%) 3453 (25.0)
Length of stay (days)
  Mean (SD) 8.44 (7.58)
  Minimum–maximum 1–149
  Median (IQR 25–75) 7 (4–11)
Number of ICD-10 conditions
  Mean (SD) 4.58 (0.92)
  Minimum–maximum 1–5
  Median (IQR 25–75) 5 (5–5)
Principal ICD-10 diagnosis
  Circulatory (%) 3336 (24.2)
  Infectious (%) 404 (2.9)
  Respiratory (%) 1444 (10.5)
  Trauma (%) 1043 (7.6)
  Tumours (%) 1505 (10.9)
Number of CHOP surgical procedures
  Mean (SD) 1.83 (1.76)
  Minimum–maximum 0–5
  Median (IQR 25–75) 1 (0–3)
Number of medicines prescribed at hospital discharge
  Mean (SD) 8.95 (3.24)
  Minimum–maximum 5–30
  Median (IQR 25–75) 8 (7.50–16.00)
CHOP, Swiss Classification of Surgical Interventions; ICD-10, 
International Classification of Diseases, 10th Revision.
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(SD=3.24) drugs were prescribed per patient at hospital 
discharge.
Associations between 30-day hospital readmission risk and 
sociodemographic characteristics and medical conditions
The rate of 30- day hospital readmission for older patients 
discharged home was 7.8%. Bivariate associations with χ2 
tests showed significant differences between older inpa-
tients’ sociodemographic characteristics and medical 
conditions (table 2). Men showed a slightly higher 
proportion of 30- day hospital readmissions than women 
(8.2% vs 7.3%). However, age did not significantly affect 
the probability of 30- day readmission. More readmissions 
were also seen among older patients with a circulatory 
disease (8.2% vs 6.5%), those not affected by trauma 
(8.0% vs 5.8%) and especially those with a tumour (15.1% 
vs 6.9%). Multimorbidity also increased the risk of 30- day 
hospital readmissions—from 1.5% for older patients with 
a single ICD-10 condition to 8.8% for those with five.
Associations between 30-day hospital readmission risk and 
drugs
On average, older patients readmitted within 30 days 
had more prescribed drugs than those who were not 
readmitted (9.95 vs 8.87 drugs). We found a linear rela-
tionship between the 30- day readmission rate and the 
average number of prescribed drugs (p>0.001), which 
supported the absence of a cut- off point in this relation-
ship (figure 1).
Among the most robust statistical associations (χ2 tests) 
with 30- day hospital readmissions involved the classes of 
drugs including antineoplastics and immunomodulators 
(12.6% vs 7.6% for those not treated with them) and anti-
emetics and antinauseants (27.7% vs 7.7%). There was 
also a higher risk of 30- day hospital readmission among 
older inpatients taking drugs for functional gastrointes-
tinal disorders (13.4% vs 7.4%) and antihypertensives 
(14.1% vs 7.7%) (table 3).
Baseline multivariate model
A baseline multivariate logistic regression model 
including older patients’ sociodemographic and clinical 
variables, but not their prescribed drugs at discharge, was 
computed to predict 30- day hospital readmission after 
discharge home (table 4). Neither sex nor age had a 
significant impact. On the contrary, LOS had a significant 
impact (OR=1.014 for each additional day; 95% CI 1.006 
to 1.021), as did mobility (OR=1.218 for older patients 
with an impaired mobility status; 95% CI 1.039 to 1.427). 
Dependence on the activities of daily living and mental 
health status showed no influence. Concerning diagnoses 
measured in the ICD-10, we found that older patients 
with a tumorous disease (OR=2.538; 95% CI 2.089 to 
3.082) were much more susceptible to 30- day hospital 
readmission. Patients with circulatory pathologies showed 
no difference from the reference category (OR=0.938; 
95% CI 0.783 to 1.124), nor did those with respiratory 
problems (OR=1.100; 95% CI 0.875 to 1.382), trauma 
Table 2 30- day hospital readmission risk at different 
periods for different age groups (N=13 802 readmissions)
Variables
30- day hospital 
readmission (%) P value
Complete sample 7.8
Sex *
  Female vs male 7.3 vs 8.2
Year- end age, in years NS
  65–69 7.5
  70–79 7.6
  80–89 8.4
  ≥90 6.4
Mobility cluster NS
  Preserved mobility vs impaired 
mobility
7.6 vs 8.5
Activities in daily living (ADL) NS
  Full ADL ability vs impaired ADL 7.8 vs 7.2
Cognitive status NS
  Preserved cognitive status vs 
cognitive impairment 7.8 vs 7.9
ICD-10 diagnosis: circulatory problems **
  No vs yes 8.2 vs 6.5
ICD-10 diagnosis: infection NS
  No vs yes 7.7 vs 9.9
ICD-10 diagnosis: respiratory problems NS
  No vs yes 7.8 vs 8.0
ICD-10 diagnosis: trauma **
  No vs yes 8.0 vs 5.8
ICD-10 diagnosis: tumour ***
  No vs yes 6.9 vs 15.1
Number of ICD-10 conditions ***
  1 1.5
  2 4.9
  3 3.6
  4 4.8
  5 8.8
Number of surgical procedures (CHOP) *
  0 7.7
  1 7.8
  2 7.0
  3 7.3
  4 7.1
  5 9.7
Year of discharge: 2015–2018 NS
  2015 8.3
  2016 8.0
  2017 8.0
  2018 6.8
*P<0.05, **P<0.01, ***P< 0.001.
CHOP, Swiss Classification of Surgical Interventions; ICD-10, 
International Classification of Diseases, 10th Revision; NS, non- 
significant.
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(OR=0.847; 95% CI 0.633 to 1.134) or infection- related 
problems (OR=1.381; 95% CI 0.964 to 1.977; p=0.078). 
Multimorbidity predicted a higher probability of readmis-
sion (OR=1.419 per additional ICD-10 condition; 95% CI 
1.282 to 1.572), whereas the number of surgical proce-
dures had no noticeable impact (OR=0.978; 95% CI 0.938 
to 1.020). The year of hospital stay did have an impact, 
however, as the earlier the hospitalisation during the 
4 years under review, the higher the probability of read-
mission (OR=0.933 per additional year; 95% CI 0.880 to 
0.990).
Some variables that were non- significant in bivariate 
analyses became significant in multivariate analyses. This 
was because the results of multivariate analyses were 
controlled by all the other parameters and interpreta-
tions were made with ‘other things being equal’. Also, the 
composition of subgroups could be very different in some 
bivariate analyses.
Prediction of 30-day hospital readmission and drug 
prescriptions
Table 5 presents the baseline logistic regression model 
completed with the drugs prescribed to older patients 
at discharge home that were significantly associated 
(p≤0.05) with 30- day hospital readmission. It was 
not possible to introduce the total number of drugs 
prescribed jointly in this model because of their collin-
earity with other drug variables. Non- significant drugs 
and other variables have been omitted from table 3 in 
order to simplify the presentation. The probabilities of 
30- day hospital readmission are presented in descending 
order of discharged older patients’ ORs for each addi-
tional unit of the drugs in question. Intake of antiemetics 
and antinauseants was very strongly linked to 30- day read-
mission (OR=3.216 for each additional drug unit taken; 
95% CI 1.842 to 5.617), as were those of antihypertensives 
(OR=1.771; 95% CI 1.287 to 2.438), gastrointestinal drugs 
(OR=1.424; 95% CI 1.166 to 1.739), systemic hormonal 
preparations (OR=1.207; 95% CI 1.052 to 1.385) and vita-
mins (OR=1.201; 95% CI 1.049 to 1.374). On the contrary, 
the intake of lipid- modifying agents was associated with a 
decrease in 30- day hospital readmissions (OR=0.841 for 
each drug from this class prescribed; 95% CI 0.732 to 
0.967).
Drug interactions and 30-day hospital readmissions
The model considered drug class interactions for the (1) 
cardiovascular system*central nervous system, gastroin-
testinal system, and metabolism*cardiovascular system; 
(2) gastrointestinal system and metabolism*central 
nervous system; (3) cardiovascular system*anti- infectives; 
and (4) central nervous system*anti- infectives. The anal-
ysis was carried out controlling for the basic model’s 
variables (table 4), and the table reports the ORs for 
each additional unit of the statistically significant drugs 
in question as well as for significant drug interactions. 
Antiemetics and antinauseants were very strongly associ-
ated with 30- day readmission (OR=3.222; 95% CI 1.844 
to 5.630), as were drugs regulating the gastrointestinal 
tract (OR=1.428; 95% CI 1.169 to 1.744) and systemic 
hormones (OR=1.210; 95% CI 1.054 to 1.390). The 
joint intake of beta- blocking agents and drugs for acid- 
related disorders was significantly associated with 30- day 
hospital readmission (OR=1.367; 95% CI 1.046 to 1.788); 
this is the only significant drug interaction in table 4. 
On the contrary, lipid- modifying agents were associated 
with lower 30- day hospital readmission (OR=0.838), as 
were substances acting on the renin–angiotensin system 
(OR=0.892; 95% CI 0.796 to 0.999) (table 6).
DISCUSSION
The present study examined the records of 20 422 hospi-
talisations involving polymedicated home- dwelling older 
patients, eventually discharged home, to identify the 
risk of 30- day hospital readmission. These records were 
obtained from 4- year data of a comprehensive hospital 
register. The 8878 individual older patients readmitted to 
the Valais Hospital showed a 30- day hospital readmission 
rate of almost 8%, corroborating previously published all- 
cause hospital readmission rates among home- dwelling 
older patients.9 27 However, Jencks et al3 found a much 
higher 30- day readmission rate, reaching almost 20% 
among discharged older patients who had been hospi-
talised in acute medicine and surgery wards.3 As a bivar-
iate association, multimorbid men were at a significantly 
higher risk of readmission than multimorbid women; 
however, in the adjusted multivariate analysis, this signifi-
cance disappeared. Medical conditions, PP and multiple 
classes of prescribed drugs were all associated with 
higher 30- day readmission rates, in line with previous 
studies.27 54–56
Our study found no significant differences in the risk of 
30- day hospital readmission for men and women. However, 
some previous research found that men were more likely 
to forget to take their drugs or to not apply the changed 
drug dosages prescribed by their family physician, conse-
quently increasing their risk of hospital readmission for 
Figure 1 Relationship between 30- day readmission rate and 
the number of prescribed drugs at discharge.
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drug- related problems.57 Opposite results were found in a 
population- based study by Manteuffel et al,58 with women 
being less likely than men to properly adhere to their drug 
prescriptions. These differences may indicate a need for 
more personalised drug prescription and drug manage-
ment to improve clinical outcomes. Further research 
should explore associations between different types of 
drugs and sex,58 59 but this topic was beyond the scope 
Table 3 30- day hospital readmissions for different classes of drugs based on ATC (N=13 802)
Drug class
30- day readmission 
with no drugs in this 
class (%)
30- day readmission 
with drugs in this 
class (%) P value
First level, anatomical main group
  Blood and blood- forming organ drugs (B) 7.1 8.0 NS
  Dermatologicals (D) 7.7 9.4 NS
  Genitourinary system and sex hormones (G) 7.7 8.3 NS
  Systemic hormonal preparations, excluding sex hormones and insulins (H) 7.4 9.5 ***
  Anti- infectives for systemic use (J) 8.0 7.2 NS
  Antineoplastic and immunomodulating agents (L) 7.6 12.6 ***
  Drugs for the musculoskeletal system (M) 8.0 6.5 *
  Antiparasitic products, insecticides and repellents (P) 7.8 6.6 ***
  Respiratory system drugs (R) 7.4 9.9 ***
  Sensory organ drugs (S) 7.8 8.4 NS
Second level, therapeutic subgroup
  Stomatological preparations (A01) 7.8 12.2 NS
  Drugs for acid- related disorders (A02) 7.0 8.5 ***
  Drugs for functional gastrointestinal disorders (A03) 7.4 13.4 ***
  Antiemetics and antinauseants (A04) 7.7 27.7 ***
  Bile and liver therapy drugs (A05) 7.8 14.3 NS
  Drugs for constipation (A06) 7.3 10.8 ***
  Antidiarrhoeals, intestinal anti- inflammatory/anti- infective agents (A07) 7.7 12.9 ***
  Digestives, including enzymes (A09) 7.8 10.0 NS
  Drugs used in diabetes (A10) 7.4 9.5 ***
  Vitamins (A11) 7.5 9.9 ***
  Mineral supplements (A12) 7.4 8.8 **
  Other alimentary tract and metabolism products (A16) 7.8 6.3 NS
  Cardiac therapy (C01) 7.6 8.9 NS
  Antihypertensives (C02) 7.7 14.1 ***
  Diuretics (C03) 7.2 9.8 ***
  Peripheral vasodilators (C04) 7.8 15.2 NS
  Vasoprotective drugs (C05) 7.8 9.8 NS
  Beta- blocking agents (C07) 7.1 8.6 ***
  Calcium channel blockers (C08) 7.7 8.6 NS
  Agents acting on the renin–angiotensin system (C09) 8.7 7.1 ***
  Lipid- modifying agents (C10) 8.3 7.1 **
  Anaesthetics (N01) 7.8 18.8 *
  Analgesics (N02) 7.8 7.8 NS
  Antiepileptics (N03) 7.7 9.0 NS
  Drugs for Parkinson’s disease (N04) 7.8 6.9 NS
  Psycholeptics (N05) 6.8 9.3 ***
  Psychoanaleptics (N06) 7.8 7.7 NS
  Other nervous system drugs (N07) 7.9 5.1 NS
*P<0.05, **P<0.01, ***P<0.001.
ATC, Anatomical Therapeutic Chemical Classification System; NS, non- significant.
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of the present study. Another interesting issue regarding 
sex differences in hospital readmission rates is the study 
window. Some studies found higher rates among men 
than among women below 3- month readmissions. More 
extended time windows (eg, 1 year) revealed no signifi-
cant sex differences.54 60 An analysis of our data set using 
a more extended readmission window might clarify this 
point and provide complementary knowledge about sex- 
associated hospital readmissions.
Our results indicated that ageing was not a risk factor 
for increased 30- day hospital readmission, in line with 
some previous publications.55 61 However, other research 
findings demonstrated that age was only positively associ-
ated with the likelihood of readmission up to 74 years old; 
above this, there no longer appeared to be any signifi-
cant relationship between age and readmission.62 63 These 
contrasting results may be explained by the studies’ 
designs, country settings, age of research populations or 
the medical conditions included.55 62 64
Longer hospital stays were also associated with a higher 
risk of hospital readmission, in line with a cohort study 
by Sud et al65 concluding that an extended hospital LOS 
was associated with increased rates of all types of readmis-
sion, except for hospitalisation after heart failure, where a 
short LOS was associated with increased rates of readmis-
sion for cardiovascular disease and heart failure.
Our results indicated a significant positive association 
between the number of a patient’s medical conditions 
and the 30- day hospital readmission rate, confirming 
other recent retrospective hospital register studies.66 67 
More specifically, older patients with impaired mobility 
showed an increased risk of hospital readmission. This 
result was not surprising, bearing in mind that although 
these older patients were discharged home—and not to 
a nursing home—after their hospital stay, their health 
status might nevertheless require future readmission. 
Indeed, this corroborated publications about older 
patients discharged after orthopaedic treatment or who 
had been initially admitted for heart failure, myocar-
dial infarction or pneumonia, but also presented with 
impaired mobility.68 69
Cognitive impairment was not associated with 
increased 30- day hospital readmission rates, in line with 
findings from the systematic review by Pickens et al,70 
which pointed out that dementia had a modest impact 
on readmission rates. It was no surprise that inpatients 
hospitalised for cancer faced a high risk of readmission, 
corroborating prior studies by Burhenn et al, Chang et al 
and Butcher.71–73
PP significantly increased the 30- day hospital readmis-
sion rate, but this result was based on the average number 
of drugs prescribed to the sample of readmitted patients 
versus those not readmitted. Although PP was confirmed 
as a strong determinant of 30- day hospital readmission in 
publications by Leendertse et al,74 75 our results showed a 
progressive linear relationship between PP and readmis-
sion rate, and this should be interpreted with caution. 
Despite our results and other publications and research 
underlining the challenge of PP among multimorbid 
older patients, there is no overall consensus about the 
best way to deal with the broad general relationship 
between PP and hospital readmission.76
Our advanced statistical analysis demonstrated that 
some specific drugs and the concomitant use of specific 
drug combinations were significantly associated with 
30- day readmission risk, although this was not unexpected 
and has been confirmed in previous publications.37 77 
Mostly in line with the research findings of Zhang et al, 
drugs including hormones, antineoplastics, immunosup-
pressors, neoplastic antibiotics and bacterial vaccines 
were substantial risk factors for hospital readmission.7
In summary, extended hospital LOS, functional impair-
ments, medical conditions and drugs have been demon-
strated to be determinants of 30- day hospital readmission, 
although not all of them have clinically or pharmacolog-
ically relevant interpretations or explanations. Further 
research involving large samples is needed, notably to 
explore the drug–drug interactions with the highest 
risk of hospital readmissions. Statistical predictions of 
Table 4 Baseline multilevel logistic regression model using 
30- day readmission (0=no; 1=yes) as the dependent variable 
associated with independent sociodemographic, LOS and 
clinical variables (N=13 802 observations for 8878 different 
inpatients readmitted to hospital)
Variables OR* P value >z 95% CI
Sex 1.079 0.285 0.938 to 1.242
Year- end age, in years 0.999 0.878 0.990 to 1.009
Hospital LOS, in days 1.014 0.000 1.006 to 1.021
Mobility cluster† 1.218 0.015 1.039 to 1.427
Dependency on the 
activities of daily living†
0.794 0.248 0.537 to 1.174
Mental health status† 0.992 0.966 0.687 to 1.433
ICD 1st diagnosis: 
circulatory problems‡
0.938 0.491 0.783 to 1.124
ICD 1st diagnosis: 
infection‡
1.381 0.078 0.964 to 1.977
ICD 1st diagnosis: 
respiratory problems‡
1.100 0.414 0.875 to 1.382
ICD 1st diagnosis: 
trauma‡
0.847 0.265 0.633 to 1.134
ICD 1st diagnosis: 
tumour‡
2.538 0.000 2.089 to 3.082
Number of ICD 1.419 0.000 1.282 to 1.572
Number of CHOP 0.978 0.304 0.938 to 1.020
Number of drugs 1.043 0.000 1.028 to 1.058
Year: 2015–2018 0.933 0.022 0.880 to 0.990




CHOP, Swiss Classification of Surgical Interventions; LOS, 
length of stay.
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potential drug–drug interactions provide important infor-
mation for modelling drug combinations and identifying 
pairs of drugs whose combination creates an exagger-
ated response.9 As the association between the number 
of drugs and the risk of hospital readmission was linear, 
more advanced inferential statistics would be needed 
to clarify a cut- off point for the mean number of drugs 
that would significantly increase the readmission rate. 
In addition, problems involving adherence to prescrip-
tions, social support networks, and stronger or weaker 
primary healthcare structures can all influence hospital 
readmission rates.39 According to some publications, 
nearly 70% of people aged over 65 make mistakes with 
their drugs.78 79 Information about drug adherence, drug 
underuse and overuse, drug changes and deprescription 
by family physicians, as well as medication management 
at home would contribute to a more comprehensive 
understanding of disease- related and drug- related 30- day 
hospital readmissions.
Table 5 Multilevel logistic regression model results for the drugs prescribed to older patients at discharge home that had 
significant predictive values (OR) for 30- day hospital readmission (controlled for variables in the baseline model: table 4) 
(N=13 802 observations for 8878 different inpatients readmitted to hospital)
Variables OR* P value >z 95% CI
First level, anatomical main group
  Blood and blood- forming organs drugs (B) 1.089 0.041 1.003 to 1.181
  Systemic hormonal preparations, excluding sex hormones and insulins (H) 1.207 0.007 1.052 to 1.385
  Respiratory system drugs (R) 1.146 0.003 1.046 to 1.254
Second level, therapeutic subgroup
  Drugs for functional gastrointestinal disorders (A03) 1.424 0.001 1.166 to 1.739
  Antiemetics and antinauseants (A04) 3.216 0.000 1.842 to 5.617
  Drugs for constipation (A06) 1.195 0.018 1.031 to 1.386
  Drugs used in diabetes (A10) 1.125 0.021 1.018 to 1.243
  Vitamins (A11) 1.201 0.008 1.049 to 1.374
  Antihypertensives (C02) 1.771 0.000 1.287 to 2.438
  Diuretics (C03) 1.149 0.024 1.018 to 1.296
  Beta- blocking agents (C07) 1.156 0.040 1.007 to 1.327
  Lipid- modifying agents (C10) 0.841 0.015 0.732 to 0.967
  Psycholeptics (N05) 1.130 0.009 1.031 to 1.238
*Adjusted OR.
Table 6 Drugs and drugs interactions from ATC classes A and B with a significant risk of 30- day hospital readmission 
(controlled for variables in the baseline model: table 4) (N=13 802 observations for 8878 different inpatients readmitted to 
hospital)
Variables OR* P value >z 95% CI
First level, anatomical main group
  Blood and blood- forming organ drugs (B) 1.089 0.040 1.004 to 1.182
  Systemic hormonal preparations, excluding sex hormones and insulins (H) 1.210 0.007 1.054 to 1.390
  Respiratory system drugs (R) 1.149 0.003 1.049 to 1.258
Second level, therapeutic subgroup
  Antiemetics and antinauseants (A04) 3.222 0.000 1.844 to 5.630
  Drugs for functional gastrointestinal disorders (A03) 1.428 0.000 1.169 to 1744
  Beta- blocking agents (C07) and drugs for acid- related disorders (A02) 1.367 0.022 1.046 to 1.788
  Drugs for constipation (A06) 1.199 0.017 1.033 to 1.392
  Agents acting on the renin–angiotensin system (C09) 0.892 0.049 0.796 to 0.999
  Lipid- modifying agents (C10) 0.838 0.013 0.729 to 0.964
*Adjusted OR.
ATC, Anatomical Therapeutic Chemical Classification System.
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Finally, it would be interesting to explore the risk of 
readmission according to different hospital wards. As 
psychiatric conditions are a frequent cause of rehospi-
talisation,80 it would be relevant for future research to 
explore registries from adult psychiatry departments and 
investigate the hospital readmission risk faced by their 
inpatients.
Strengths and limitations
This study’s main strength was its use of data recorded 
in a comprehensive register. We consider this retrospec-
tive study useful for clinical practice and future research 
because a whole series of sociodemographic and clinical 
parameters, medical conditions, and prescribed drugs 
were used to predict the probability of hospital read-
mission. Using both bivariate and multivariate analyses 
enabled an evaluation of the data’s longitudinal nature.
Our study had several limitations, nevertheless. The 
design did not allow us to identify hospitalisations and 
readmissions lost to follow- up and to adjust our data 
for death outside the hospital. We were also unable to 
identify unnecessary hospitalisations or any bias towards 
hospitalisation rather than another healthcare solution 
for older inpatients. Our data set could not inform us 
about whether older inpatients had been first admitted 
to another hospital or were subsequently readmitted 
elsewhere during the study period. Because the reasons 
for hospital admission are not chosen from a list but are 
entered into the register as free descriptive text, these 
factors were not part of our data set, and the study was 
unable to explore the reasons for an admission’s impact 
on 30- day rehospitalisation. Another limitation was the 
study’s lack of formal screening methods to explain ADEs 
in detail, and it was impossible to distinguish between 
elective and urgent hospitalisations. Although the study 
considered statistical associations between drugs and 
rehospitalisations, it did not use clinically diagnosed 
drug–drug interactions. Finally, we were unable to 
consider any potential causality between PP and hospital 
readmission.
CONCLUSIONS
Hospital LOS, medical conditions, functional impair-
ments and prescribed drugs were all critical factors in 
predicting hospital readmissions, thus affirming our 
hypotheses. Readmission patterns are complex and 
poorly understood because older patients often present 
with multiple chronic conditions, functional impairments 
and complex drug prescriptions. Hospital readmission is 
an underinvestigated topic deserving of additional, well- 
conducted, predictive research exploiting accurate longi-
tudinal data from large samples.
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Supplementary table. Descriptive statistics of drugs prescribed per hospital stays (N = 13,802 readmissions) at 
discharge based on the ATC Classification System. 
Drug classes based on the ATC Classification System 
Min-Max Mean (SD) 
First level, anatomical main group 
Blood and blood forming organs (B)   0–5 1.15 (0.86) 
Dermatologicals (D) 0–3 0.04 (0.21) 
Genitourinary system and sex hormones (G) 0–4 0.21 (0.47) 
Systemic hormonal preparations, excl. sex hormones and insulins (H) 0–4 0.20 (0.46) 
Anti-infectives for systemic use (J) 0–4 0.24 (0.47) 
Antineoplastic and immunomodulating agents (L) 0–5 0.05 (0.23) 
Musculo-skeletal system (M) 0–3 0.15 (0.39) 
Antiparasitic products, insecticides and repellents (P) 0–2 0.02 (0.13) 
Respiratory system (R) 0–7 0.28 (0.72) 
Sensory organs (S) 0–6 0.10 (0.39) 
Second level, therapeutic subgroup 
Stomatological preparations (A01) 0–1 0.00 (0.06) 
Drugs for acid-related disorders (A02) 0–3 0.56 (0.52) 
Drugs for functional gastrointestinal disorders (A03) 0–3 0.07 (0.28) 
Antiemetics and antinauseants (A04) 0–1 0.01 (0.08) 
Bile and liver therapy (A05) 0–1 0.00 (0.05) 
Drugs for constipation (A06) 0–3 0.15 (0.40) 
Antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents (A07) 0–2 0.03 (0.18) 
Digestives, incl. Enzymes (A09) 0–2 0.02 (0.13) 
Drugs used in diabetes (A10) 0–5 0.26 (0.63) 
Vitamins (A11) 0–4 0.15 (0.44) 
Mineral supplements (A12) 0–3 0.29 (0.51) 
Other alimentary tract and metabolism products (A16) 0–1 0.00 (0.05) 
Cardiac therapy drugs (C01) 0–4 0.14 (0.42) 
Antihypertensives (C02) 0–2 0.02 (0.17) 
Diuretics (C03) 0–3 0.27 (0.53) 
Peripheral vasodilators (C04) 0–1 0.00 (0.06) 
Vasoprotectives (C05) 0–3 0.02 (0.14) 
Beta-blocking agents (C07) 0–2 0.46 (0.51) 
Calcium channel blockers (C08) 0–2 0.16 (0.37) 
Agents acting on the renin-angiotensin system (C09) 0–3 0.64 (0.62) 
Lipid modifying agents (C10) 0–3 0.43 (0.52) 
Anaesthetics (N01) 0–1 0.00 (0.05) 
Analgaesics (N02) 0–7 1.02 (0.91) 
Antiepileptics (N03) 0–5 0.11 (0.35) 
Drugs for Parkinson’s disease (N04) 0–5 0.04 (0.24) 
Psycholeptics (N05) 0–6 0.53 (0.73) 
Psychoanaleptics (N06) 0–3 0.20 (0.44) 
Other nervous system drugs(N07) 0–3 0.03 (0.19) 
Total number of drugs 5–30 8.95 (3.24) 
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